Inhibrx Biosciences (INBX) EBITDA Margin Growth (1y) (2024 - 2025)
Powered by 
Analysis
Inhibrx Biosciences (INBX) EBITDA Margin Growth (1y) (2024 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -1,651.00 |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 29,091.00 |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 15.88 Mn |
| Dec 31, 2024 | -4.45 Mn |
| Jun 30, 2024 | -2.31 Mn |